Differential effects of metformin on age related comorbidities in older men with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 31, Issue 4, 2017, Pages 679-686

  Wang, Chen Pin ^a,b   Lorenzo, Carlos ^a   Habib, Samy L ^b,c   Jo, Booil ^d   Espinoza, Sara E ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Comorbidity; Frailty; Metformin; Mortality; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ARTICLE; BODY MASS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DEMENTIA; DEPRESSION; DIASTOLIC BLOOD PRESSURE; FRAILTY; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES; VETERAN; AGING; BLOOD; DRUG RESISTANCE; ELECTRONIC HEALTH RECORD; FRAIL ELDERLY; GOVERNMENT; LONGITUDINAL STUDY; MORTALITY; NEOPLASM; PREVALENCE; RISK; VERY ELDERLY; VETERANS HEALTH;

AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DEMENTIA; DEPRESSION; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; ELECTRONIC HEALTH RECORDS; FRAIL ELDERLY; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; METFORMIN; MORTALITY; NEOPLASMS; PREVALENCE; RISK; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH;

EID: 85012875479     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.01.013     Document Type: Article

References (50)

1. Barzilay, J.I., Blaum, C., Moore, T., Xue, Q.L., Hirsch, C.H., Walston, J.D., Fried, L.P., Insulin resistance and inflammation as precursors of frailty: The Cardiovascular Health Study. Archives of Internal Medicine 167:7 (2007), 635–641, 10.1001/archinte.167.7.635 (PMID: 17420420).
2. Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Meigs, J.B.,.. Muggeo, M., Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: The Bruneck study. Diabetes Care 30 (2007), 318–324, 10.2337/dc06-0919 (PMID: 17259501).
3. Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.P.,.. Cornu, C., Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Medicine, 9(4), 2012, e1001204, 10.1371/journal.pmed.1001204.
4. Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 40:5 (1987), 373–383.
5. Chen, Y., Teranishi, K., Li, S., Yee, S.W., Hesselson, S., Stryke, D.,.. Giacomini, K.M., Genetic variants in multidrug and toxic compound extrusion 1, hMATE1, Alter transport function. The Pharmacogenomics Journal 9 (2009), 127–136, 10.1038/tpj.2008.19.
6. Currie, C.J., Poole, C.D., Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:9 (2009), 1766–1777, 10.1007/s00125-009-1440-6.
7. De Felice, F.G., Ferreira, S.T., Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63:7 (2014), 2262–2272, 10.2337/db13-1954.
8. Djiogue, S., Nwabo Kamdje, A.H., Vecchio, L., Kipanyula, M.J., Farahna, M., Aldebasi, Y., Seke Etet, P.F., Insulin resistance and cancer: The role of insulin and IGFs. Endocrine-Related Cancer 20 (2013), R1–R17, 10.1530/ERC-12-0324 (PMID: 23207292).
9. Espinoza, S.E., Jung, I., Hazuda, H., Frailty transitions in the San Antonio longitudinal study of aging. Journal of the American Geriatrics Society 60:4 (2012), 652–660, 10.1111/j.1532-5415.2011.03882.x.
10. Fortin, M., Bravo, G., Hudon, C., Lapointe, L., Almirall, J., Dubois, M.F., Vanasse, A., Relationship between multimorbidity and health-related quality of life of patients in primary care. Quality of Life Research 15 (2006), 83–91, 10.1007/s11136–005-8661-z (PMID: 16411033).
11. Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., Dunn, B.K., Ford, L., DeCensi, A, Szabo, E., Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer prevention research (Philadelphia, Pa) 7:9 (2014), 867–885, 10.1158/1940–6207.CAPR-13-0424.
12. Gijsen, R., Hoeymans, N., Schellevis, F.G., Ruwaard, D., Satariano, W.A., van den Bos, G.A., Causes and consequences of comorbidity: A review. Journal of Clinical Epidemiology 54 (2001), 661–674, 10.1016/S0895-4356(00)00363-2.
13. Gremese, E., Ferraccioli, G., The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmunity Reviews 10:10 (2011), 582–589, 10.1016/j.autrev.2011.04.018.
14. Guo, M., Mi, J., Jiang, Q.M., Xu, J.M., Tang, Y.Y., Tian, G., Wang, B., Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clinical and Experimental Pharmacology & Physiology 41:9 (2014), 650–656.
15. Gupta, A., Bisht, B., Dey, C.S., Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60 (2011), 910–920, 10.1016/j.neuropharm.2011.01.033.
16. Hanley, A.J., Williams, K., Stern, M.P., Haffner, S.M., Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio heart study. Diabetes Care 25:7 (2002), 1177–1184 (PMID: 12087016).
17. Haroon, E., Raison, C.L., Miller, A.H., Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology Reviews 37 (2012), 137–162, 10.1038/npp.2011.205.
18. Holden, S.E., Jenkins-Jones, S., Currie, C.J., Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: A retrospective cohort study. PloS One, 11(5), 2016, e0153594, 10.1371/journal.pone.0153594.
19. Hsu, C.C., Wahlqvist, M.L., Lee, M.S., Tsai, H.N., Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. Journal of Alzheimer's Disease 24 (2011), 485–493, 10.3233/JAD-2011-101524.
20. Imfeld, P., Bodmer, M., Jick, S.S., Meier, C.R., Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A population-based case–control study. Journal of the American Geriatrics Society 60:5 (2012), 916–921, 10.1111/j.1532-5415.2012.03916.x.
21. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M.,.. Groop, L., Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001), 683–689, 10.2337/diacare.24.4.683.
22. Jablonski, K.A., McAteer, J.B., de Bakker, P.I.W., Franks, P.W., Pollin, T.I., Hanson, R.L.,.. for the Diabetes Prevention Program Research Group., Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59:10 (2010), 2672–2681, 10.2337/db10-0543.
23. Jacob, L., Kostev, K., Rathmann, W., Kalder, M., Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. Journal of Diabetes and its Complications 30:6 (2016), 1056–1059, 10.1016/j.jdiacomp.2016.04.003.
24. Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J.,.. Schweiger, S., Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proceedings of the National Academy of Sciences of the United States of America (PNAS) 107 (2010), 21830–21835, 10.1073/pnas.0912793107.
25. Kowall, B., Rathmann, W., Kostev, K., Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care 38:1 (2015), 59–65.
26. Lamanna, C., Monami, M., Marchionni, N., Mannucci, E., Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 13:3 (2011), 221–228, 10.1111/j.1463-1326.2010.01349.x.
27. Lehman, D.M., Lorenzo, C., Hernandez, J., Wang, C.P., Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 35 (2012), 1002–1007, 10.2337/dc11-1829.
28. Liccini, A., Malmstrom, T.K., Morley, J.E., Metformin use and cognitive dysfunction among patients with diabetes mellitus. Journal of the American Medical Directors Association 17:11 (2016), 1063–1065, 10.1016/j.jamda.2016.08.026.
29. Mellbin, L.G., Malmberg, K., Norhammar, A., Wedel, H., Ryden, L., Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: Experiences from an extended follow-up of the diabetes mellitus insulin-glucose infusion in acute myocardial infarction (DIGAMI) 2 study. Diabetologia 54 (2011), 1308–1317, 10.1007/s00125-011-2084-x.
30. Moore, E.M., Mander, A.G., Ames, D., Kotowicz, M.A., Carne, R.P., Brodaty HWoodward, M.,.. Investigators, A.I.B.L., Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36 (2013), 2981–2987, 10.2337/dc13-0229.
31. National Center for Health Statistics, Available at: http://www.cdc.gov/nchs.
32. National Center for Health Statistics, CDC. ICD-9-CM guidelines, conversion table, and addenda. Classification of diseases, functioning, and disability. (Retrieved 2017–02-04).
33. Novosyadlyy, R., LeRoith, D., Hyperinsulinemia and type 2 diabetes: Impact on cancer. Cell Cycle 9 (2010), 1449–1450, 10.4161/cc.9.8.11512 (PMID: 20372078).
34. Pugh, J.A., Wang, C.P., Espinoza, S.E., Noel, P.H., Bollinger, M., Amuan, M.,.. Pugh, M.J., Influence of frailty-related diagnoses, high-risk prescribing in elderly adults, and primary care use on readmissions in fewer than 30 days for veterans aged 65 and older. Journal of the American Geriatrics Society 62:2 (2014), 291–298.
35. Rao, A.D., Kuhadiya, N., Reynolds, K., Fonseca, V.A., Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. Diabetes Care 31:8 (2008), 1672–1678, 10.2337/dc08-0167.
36. Reiber, G.E., Boyko, E.J., Diabetes research in the Department of Veterans Affairs. Diabetes Care 27:Suppl. 2 (2004), b95–b98, 10.2337/diacare.27.suppl_2.B95.
37. Sahra, I.B., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P.,.. Bost, F., Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Research 70 (2010), 2465–2475, 10.1158/0008-5472.CAN-09-2782.
38. Stuart, M.J., Baune, B.T., Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neuroscience & Biobehavioral Reviews 36 (2012), 658–676, 10.1016/j.neubiorev.2011.10.001 (PMID: 22020230).
39. Thakkar, B., Aronis, K.N., Vamvini, M.T., Shields, K., Mantzoros, C.S., Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: A meta-analysis using primary data of published studies. Metabolism: Clinical and Experimental 62:7 (2013), 922–934 (PMID: 23419783).
40. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) group. Lancet 352:9131 (1998), 854–865, 10.1016/S0140-6736(98)07037-8.
41. Wang, C.P., Jo, B., Brown, C.H., Causal inference in longitudinal comparative effectiveness studies with repeated measures of a continuous intermediate variable. Statistics in Medicine 33:20 (2014), 3509–3527.
42. Wang, C.P., Lorenzo, C., Espinoza, S.E., Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. Journal of Endocrinology, Diabetes & Obesity, 2(2), 2014, 1031 (PMID: 25506599).
43. Wang, J., Gallagher, D., Devito, L.M., Cancino, G.I., Tsui, D., He, L.,.. Miller, F.D., Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11 (2012), 23–35, 10.1016/j.stem.2012.03.016.
44. West, D.S., Elaine Prewitt, T., Bursac, Z., Felix, H.C., Weight loss of black, white, and Hispanic men and women in the diabetes prevention program. Obesity 16:6 (2008), 1413–1420, 10.1038/oby.2008.224 (PMID:18421273).
45. Wilson, P.W.F., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factors categories. Circulation 97 (1998), 1837–1847, 10.1161/01.CIR.97.18.1837.
46. Wnsperger, N.F., Metformin: Intrinsic vasculoprotective properties. Diabetes Technology & Therapeutics 2 (2000), 259–272.
47. Wolff, J., Starfield, B., Anderson, G., Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. JAMA Internal Medicine 162 (2002), 2269–2276, 10.1001/archinte.162.20.2269.
48. Wright, J.L., Stanford, J.L., Metformin use and prostate cancer in Caucasian men: Results from a population-based case–control study. Cancer Causes & Control 20:9 (2009), 1617–1622, 10.1007/s10552-009-9407-y.
49. Zakikhani, M., Dowling, R., Fantus, I.G., Sonenberg, N., Pollak, M., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 66 (2006), 10269–10273 (PMID: 17062558).
50. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., EMPA-REG OUTCOME Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 373 (2015), 2117–2128.